Disease Modifying Approaches for Alzheimers Pathology
The DOI matches its Crossref record.
Abstract
Alzheimer's disease (AD) is the most common age-associated neurodegenerative disease in the world. The major neuropathological features of AD are synaptic loss, neuronal loss, neurofibrillary tangles and the deposition of amyloid-beta (Abeta) as plaques and in cerebral blood vessels. Numerous Abeta targeting therapeutic approaches have been shown to prevent amyloid deposition and resulting in cognitive improvement in transgenic mouse models of AD. Some of these approaches are currently in early clinical trials. It remains to be seen if these approaches will be proven effective in patients. Future anti-AD therapies will likely be multi-modal and individually tailored depending on the patient's immune status, genetic background and their amyloid burden, as determined by imaging studies using Abeta specific labeling ligands. Pre-clinical data suggests that it will be much more feasible to prevent AD related pathology, then to clear existing pathology, making early diagnosis critically important.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Immunotherapeutic Approaches for Alzheimer’s Disease
Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284
“The first in vivo immunization trial, reported in a seminal paper by Schenk et al. (1999) demonstrated that full-length, aggregated Ab1–42 in conjunction with Freund’s adjuvant could reduce plaque load in vivo, which at the time was hypothesized to be the main culprit in AD pathology (Schenk et al.”
Amyloid-β immunisation for Alzheimer's disease
Wisniewski, T., & Konietzko, U. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70170-4 · Cited by 155
AD Vaccines: Conclusions and Future Directions
Wisniewski, T. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787847289 · Cited by 14
“It appeared that the immune reaction triggered by AN1792 was a double-edge sword, where the benefits of a humoral response against Aβ were overshadowed in some individuals by a detrimental Th1 mediated inflammatory response [7, 13].”
Background
Metadata
- Authors
- Sadowski, M., & Wisniewski, T.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2007-07-01
- Volume
- 13
- Issue
- 19
- Pages
- 1943-1954
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2005789680
- Cited by
- 39
- References
- 0
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Disease Modifying Approaches for Alzheimers Pathology. https://app.cochat.ai/papers/10.2174/138161207781039788
- The paper
- Sadowski, M., & Wisniewski, T. (2007). Disease Modifying Approaches for Alzheimers Pathology. Current Pharmaceutical Design. https://doi.org/10.2174/138161207781039788
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.